Lv1
14 积分 2024-01-24 加入
Efficacy and Safety of Emerging Immunotherapies in Psoriasis
2天前
已完结
Efficacy and Safety of Emerging Immunotherapies in Psoriasis
2天前
已关闭
Efficacy and Safety of Emerging Immunotherapies in Psoriasis
2天前
已关闭
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
1个月前
已完结
Psoriasis
1个月前
已完结
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
FLAIR: A Phase II, Open label, Randomized Study of Osimertinib Plus Bevacizumab versus Osimertinib in Recurrent or Metastatic Treatment-naïve NSCLC Patients Harboring EGFR 21L858R Mutation
3个月前
已完结
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
3个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
皖公网安备34019202002308
